CELC Celcuity Inc

$CELC I learned my lesson from CORT. When a company is generating $750M off a single drug, buy the F OUT OF IT when it dumps during the wider market or a short term binary event $CORT now up 300% in just a year 😭

$CELC This is a complete nothingburger. Standard boilerplate risk disclosure following FDA approval, not evidence of any actual patent challenge. REVTORPYK has NCE exclusivity through 2031, with additional patents extending into 2041–2042. No pending litigation, no imminent generic competition. You’re presenting routine post-approval disclosures as some new bearish development when they actually reflect CELC’s transition into a commercial-stage biotech. Nice try.

$CELC “Additionally, the median duration of response was over 19 months for the gedatolisib triplet in both the PIK3CA wild-type cohort, or Study 1, and the PIK3CA mutant cohort, or Study 2, compared to not evaluable for fulvestrant in the PIK3CA wild-type cohort and 7.5 months for alpelisib plus fulvestrant in the PIK3CA mutant cohort. To our knowledge, the gedatolisib triplet in each study demonstrated the longest median duration of response results ever reported for a therapeutic regimen used in the primary analysis for a Phase 3 trial in the second-line HR+/HER2- advanced breast cancer setting.”

$CELC 30k per vial, lasts a month, and the mDoR is 19 months. Lol. How is this not a $200 stock.

$CELC I have a feeling this is going to fly soon. Let's see where the price is in a month. (Not that my feelings have a great winning percentage...)

$CELC real world experience shows without fail: patients take the most efficacious option available within their safety limit. Not one takes an inferior drug out of better safety or convenience in this setting, and most patients live near treatment centers. Therefore this selling has little to do with "fundamentals". It's about being a massive loser that funds must cut due to mandates. Hopefully a few quarters of sales will change perception on the stock. I believe CELC is a $150 company today.

$CELC $INO A small positive catalyst will force them to panic-cover before they bleed out on interest fees. 4. Fundamental Paradigm Shift INO just received historic FDA approval for Voceryq (the first plasmid DNA therapy). They also won an $80.4 million arbitration award. The company has shifted from a "risky biotech with no revenue" to a "commercial company with cash." The market is still digesting this, and short-sellers are fighting a fundamentally changed reality. 5. Technical Breakout Potential The stock is holding support around $1.70–$1.75. If it breaks the key resistance level at $2.10–$2.20 on high volume, it will trigger algorithmic buying and stop-loss covering from the 44% short volume. The next targets would be $2.50**, followed by the consensus price target of **$3.00+. 💡 The Bottom Line for a Day Trader: The setup is a classic "powder keg." You have a tiny float, a 263% borrow fee, nearly 45% of daily volume being shorted, and a massive fundamental catalyst.

$CELC The sNDA application for the mutation cohort was submitted to the NDA on 08/26/2026. Normally, the deadline for a response regarding the acceptance of an sNDA is 60 days. Accordingly, Celcuity should have received the response by yesterday at the latest. Why hasn't there been any update from Celcuity yet?

$CELC The new data announced today is for the new drug indication application which was submitted to the FDA August 27. The FDA is scheduled to rule on the PDUFA date this coming week. Is a double dose of good fortune in store?

$CELC THIS IS ABSOLUTELY MASSIVE. 🚀🔥 Wall Street needs to wake up to what Celcuity just delivered at ESMO. Phase 3 VIKTORIA-1 results: 🔥 21.5 months progression-free survival vs. just 9.1 months for the competing regimen. 🔥 54% reduction in risk of progression or death in patients without liver metastases. 🔥 59% response rate vs. 33% for the comparator. 🔥 19.4 MONTHS median response duration vs. just 7.5 months. 🔥 Only 5% discontinued gedatolisib due to adverse events vs. 19% discontinuing alpelisib. And here’s the kicker: REVTORPYK is ALREADY FDA APPROVED for PIK3CA wild-type breast cancer. The mutant population represents a potential SECOND commercial opportunity, with an FDA application already submitted. This isn’t some speculative preclinical biotech story anymore. This is a commercial-stage oncology company delivering compelling Phase 3 evidence against an established competitor. $CELC 🚀💎

$CELC Can’t believe it was less than a week ago that Chartistmind, who claimed to be right 7300 times, guaranteed that CELC was going down to $50. When I questioned his credibility, he blocked me, so I don’t know what he has posted since. Anyway….it’s comforting to see the recent price action.

$CELC Citizens reiterated its $177.00 price target and Market Outperform rating for Celcuity Inc. (NASDAQ: CELC) yesterday, October 28, 2026.

$CELC What a summary free dashboard gave me all the information I needed. Thanks to Free app finpile

$CELC high chance to become the 1L aBC backbone as well in roughly 3 years. 1L is 2x larger than 2nd line. At 40% 2L penetration, CELC is a 7.5B enterprise value today. Would become 15B when 1st line reads out. And the PoS there is high. SubQ formulation will remove issue with IV injection. A BP with strong sales team can unlock more value with distribution, making the value of their purchase worth 20B relative to the 15B they paid. A 10B buyout today therefore makes a lot of sense, would easily clear BP hurdle rate.

Cantor🏁 $CELC Overweight; PT $140 $FTH $RLAY RHHBY AZN Cantor said in its initiation report: Celcuity is a commercial-stage oncology company that recently launched its first product, Revtorpyk (gedatolisib), a dual pan-PI3K/mTOR inhibitor, in second-line (2L) HR+/HER2- breast cancer. The initial approval covers PIK3CA-wildtype patients (~60% of the 2L population), with an expected expansion into PIK3CA-mutant disease next year that would address the entire 2L population. We view Celcuity as one of the few commercial-stage oncology companies with a credible path to multi-billion-dollar peak sales, offering investors an attractive launch driven growth story with additional strategic optionality.

$CELC Short interest still on the high side, but shows a drop for the first time in a long time.

$CELC Celcuity presents updated Phase 3 VIKTORIA-1 subgroup data for gedatolisib in HR+/HER2- breast cancer (65.25 -0.32) Updated Phase 3 VIKTORIA-1 analyses showed gedatolisib-based regimens improved progression-free survival versus alpelisib plus fulvestrant across liver and visceral metastasis subgroups in PIK3CA-mutant advanced breast cancer. In patients without liver metastases, median PFS was 21.5 months for the gedatolisib triplet and 11.5 months for the doublet versus 9.1 months for alpelisib plus fulvestrant. Objective response rates in the PIK3CA-mutant cohort were 59% for the triplet and 43% for the doublet versus 33% for control; median duration of response was 19.4, 27.8, and 7.5 months, respectively. Discontinuation due to treatment-emergent adverse events was 5% for the triplet and 4% for the doublet versus 19% for alpelisib.

$CELC 🏥 Celcuity presented updated Phase 3 VIKTORIA-1 results showing gedatolisib triplet and doublet achieved median PFS of 21.5 and 11.5 months versus 9.1 months for alpelisib plus fulvestrant, with ORR of 59% and 43% versus 33%, respectively, in HR+/HER2- advanced breast cancer patients without liver metastases. Market-relevant event

$CELC A few days now of holding up very well as rest of biotech gets sold off. Fingers crossed we have turned a corner here.

$CELC 🏥 Celcuity presented updated Phase 1b/2 data for gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer, with median rPFS of 15.7 months and rPFS6 of 82.2% after prior abiraterone and median rPFS of 9.1 months and rPFS6 of 62.5% after prior enzalutamide.